Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

739.57
-2.5500-0.34%
Post-market: 737.72-1.8500-0.25%18:42 EDT
Volume:500.28K
Turnover:367.34M
Market Cap:76.14B
PE:18.29
High:744.50
Open:742.12
Low:723.65
Close:742.12
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:0.70
T/O Rate:0.51%
Dividend:3.64
Dividend Rate:0.49%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.40
PE(LYR):17.83

Loading ...

US FDA Approves Mirum's Drug for Rare Bone Disorder

Reuters
·
Sep 26

Regeneron Steps Into Obesity Drug Race With New Phase 1 Study

TIPRANKS
·
Sep 26

Regeneron to Report Q3 Results, Host Conference Call and Webcast

Reuters
·
Sep 25

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

GlobeNewswire
·
Sep 25

Regeneron Approaching Incremental Catalysts Like Upcoming Olatorepatide Data Readout, RBC Says

MT Newswires Live
·
Sep 24

Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%

Tiger Newspress
·
Sep 24

Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 22

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 15

Regeneron and Sanofi Complete Key Dupilumab Itch Study, Expanding Dermatology Upside

TIPRANKS
·
Sep 12

S&P 500 Futures up in Premarket Trading; South Bow, Oracle Lead

Dow Jones
·
Sep 11

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 11

Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says

MT Newswires Live
·
Sep 10

Sanofi, Regeneron Could Extend Dupixent Patent

Dow Jones
·
Sep 09

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $920 From $800, Keeps Outperform Rating

MT Newswires Live
·
Sep 09

Regeneron Pharmaceuticals, Inc. : Bmo Raises Target Price to $920 from $800

THOMSON REUTERS
·
Sep 09

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 09

CytomX Highlights Varseta-M EpCAM Topo-1 ADC Data in Late-Line Metastatic Colorectal Cancer Presentation

Reuters
·
Sep 09

Regeneron Director Kathryn Guarini Disposes of 400 Common Shares Worth $340,000

Reuters
·
Sep 04

Regeneron Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 04

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-09-02

Reuters
·
Sep 03